Published in Blood Weekly, July 13th, 2006
MiRNAs are a recently discovered class of natural antisense RNAs that are important in the regulation of cellular functions. These data demonstrate that antisense inhibition is a powerful technique to regulate the function of miRNAs and suggest that miR-122 may be an attractive therapeutic target for cardiovascular and metabolic diseases.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.